Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALNANASDAQ:BCDANASDAQ:ELOXOTCMKTS:ENZNNASDAQ:IDRA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNAAllena Pharmaceuticals$0.07$0.06▼$1.17$37K1.1315.69 million shs96,558 shsBCDABioCardia$0.38+2.7%$0.42$0.36▼$2.92$10.13M1.47337,584 shs62,010 shsELOXEloxx Pharmaceuticals$0.94-2.1%$0.92$0.40▼$10.90$2.95M2.759,321 shs8,256 shsENZNEnzon Pharmaceuticals$0.07$0.08$0.06▼$0.23N/A0.3314,719 shsN/AIDRAIdera Pharmaceuticals$0.50$0.22▼$8.67$450.52M1.25464,030 shs21,870 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNAAllena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BCDABioCardia+1.04%-7.98%-4.71%-36.02%-81.60%ELOXEloxx Pharmaceuticals-2.52%-4.70%-10.05%-18.43%-87.66%ENZNEnzon Pharmaceuticals+11.73%-23.63%-12.56%-31.05%-67.09%IDRAIdera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABCDABioCardia1.6787 of 5 stars3.35.00.00.00.02.50.0ELOXEloxx Pharmaceuticals0.4628 of 5 stars2.00.00.00.01.91.70.6ENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNAAllena PharmaceuticalsN/AN/AN/AN/ABCDABioCardia2.50Moderate Buy$4.00961.01% UpsideELOXEloxx PharmaceuticalsN/AN/A$55.005,751.06% UpsideENZNEnzon PharmaceuticalsN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNAAllena PharmaceuticalsN/AN/AN/AN/A$0.23 per shareN/ABCDABioCardia$480K21.10N/AN/A($0.07) per share-5.39ELOXEloxx PharmaceuticalsN/AN/AN/AN/A($4.92) per shareN/AENZNEnzon Pharmaceuticals$30KN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/A0.29$0.56 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNAAllena Pharmaceuticals-$48.66MN/A0.00N/AN/AN/A-287.46%-146.58%N/ABCDABioCardia-$11.57M-$0.55N/AN/AN/A-2,425.79%-3,638.68%-228.55%5/8/2024 (Estimated)ELOXEloxx Pharmaceuticals-$36.06M-$9.07N/AN/AN/AN/AN/A-203.00%N/AENZNEnzon Pharmaceuticals$1.37M$0.017.24∞N/AN/A46.47%2.92%N/AIDRAIdera Pharmaceuticals$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/ALatest IDRA, ALNA, ENZN, ELOX, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024Q4 2023ENZNEnzon PharmaceuticalsN/A$0.01+$0.01$0.01N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALNAAllena PharmaceuticalsN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/AELOXEloxx PharmaceuticalsN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNAAllena PharmaceuticalsN/A1.581.58BCDABioCardiaN/A0.400.40ELOXEloxx PharmaceuticalsN/A0.240.24ENZNEnzon PharmaceuticalsN/A27.6227.62IDRAIdera PharmaceuticalsN/A1.561.56OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNAAllena Pharmaceuticals7.33%BCDABioCardia20.57%ELOXEloxx Pharmaceuticals2.90%ENZNEnzon PharmaceuticalsN/AIDRAIdera Pharmaceuticals12.18%Insider OwnershipCompanyInsider OwnershipALNAAllena Pharmaceuticals3.70%BCDABioCardia23.90%ELOXEloxx Pharmaceuticals20.20%ENZNEnzon Pharmaceuticals0.27%IDRAIdera Pharmaceuticals5.05%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALNAAllena Pharmaceuticals35122.08 million117.57 millionNot OptionableBCDABioCardia1626.87 million20.34 millionOptionableELOXEloxx Pharmaceuticals183.14 million2.51 millionNot OptionableENZNEnzon PharmaceuticalsN/AN/AN/ANot OptionableIDRAIdera Pharmaceuticals3262.36 million59.21 millionOptionableIDRA, ALNA, ENZN, ELOX, and BCDA HeadlinesSourceHeadlineEkso Bionics (NASDAQ: EKSO)fool.com - April 11 at 12:41 PMKiniksa Pharmaceuticalsforbes.com - November 15 at 3:23 PMIdra Pin Codeindiatvnews.com - August 24 at 7:09 PMNabriva Therapeutics AG (NBRVF)investing.com - August 9 at 2:08 AMTesla's Switch to Giga Press Die Castings for Model 3 Eliminates 370 Partsdesignnews.com - May 21 at 8:54 AMMarginalianpr.org - April 26 at 9:17 PMA mysterious rift propels the story in ‘Take What You Need’washingtonpost.com - March 17 at 5:57 PMIdera Pharmaceuticals, Inc.: Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlookfinanznachrichten.de - January 18 at 7:34 AMIdera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic ...bakersfield.com - January 17 at 11:33 AMIdera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlookfinance.yahoo.com - January 17 at 11:33 AMWhy Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionmsn.com - January 10 at 7:29 PMIdera (IDRA) Stock Soars on GlaxoSmithKline Partnershipthestreet.com - January 4 at 12:55 PMIdera Pharmaceuticals, Inc.: Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Updatefinanznachrichten.de - November 18 at 3:52 PMIdera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 14 at 5:55 PMIdera Pharma Acquires Rare Disease Player, Names New CEOfinance.yahoo.com - September 29 at 3:46 PMIdera Pharma Shares Rise Nearly 18% After Aceragen Acquisitionmarketwatch.com - September 28 at 6:34 PMIdera Pharmaceuticals Acquires Aceragenfinance.yahoo.com - September 28 at 6:34 PMIdera Pharmaceuticals Stock (NASDAQ:IDRA), Dividendsbenzinga.com - September 27 at 10:32 PMIdera Pharmaceuticals Reports Second Quarter 2022 Financial Resultsfinance.yahoo.com - August 9 at 9:26 PMIdera Pharmaceuticals Inc. [IDRA] Is Currently 16.02 above its 200 Period Moving Avg: What Does This Mean?dbtnews.com - May 18 at 5:18 PMIdera halts melanoma trial for cancer candidate after early positive resultsseekingalpha.com - May 17 at 6:10 PMWhy Are Idera Pharmaceuticals Shares Soaring Todayfinance.yahoo.com - May 17 at 6:10 PMIdera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMCfinance.yahoo.com - May 17 at 8:18 AMIdera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 5 at 6:17 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAllena PharmaceuticalsNASDAQ:ALNAAllena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.BioCardiaNASDAQ:BCDABioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.Eloxx PharmaceuticalsNASDAQ:ELOXEloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.Enzon PharmaceuticalsOTCMKTS:ENZNEnzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.Idera PharmaceuticalsNASDAQ:IDRAAceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.